Today: 9 June 2026
CapitaLand Investment stock price ticks up near 52-week high as investors parse filings and eye Feb 11 results
30 January 2026
2 mins read

CapitaLand Investment stock price ticks up near 52-week high as investors parse filings and eye Feb 11 results

Singapore, Jan 30, 2026, 15:08 SGT — Regular session

  • Shares of CapitaLand Investment edged up 0.3% to S$3.09 in afternoon trading
  • SGX filing reveals 317,809 share awards granted to non-executive directors, to be settled using treasury shares
  • Investors are eyeing Singapore’s policy cues and gearing up for CLI’s full-year earnings report on Feb. 11

Shares of CapitaLand Investment edged up 0.3% to S$3.09 by Friday afternoon, hitting the upper end of the day’s S$3.05–S$3.09 range. The price hovered just below a 52-week peak of S$3.11, on volume near 7.76 million shares.

The decision follows Singapore’s central bank holding policy steady yesterday while flagging that growth and inflation risks remain “tilted to the upside.” Economists saw this wording as less dovish than anticipated. OCBC’s Selena Ling described the tone as “a tad more hawkish and less dovish.” Reuters

CapitaLand Investment finds itself right in the thick of reporting season for CapitaLand-managed trusts. Investors are hunting for signals on asset valuations and fee trends ahead of the parent company’s year-end results. Timing, it seems, is everything.

A filing late Wednesday revealed the company granted 317,809 shares to non-executive directors under its restricted share plan. These awards vested immediately through a transfer of treasury shares—the stock the firm holds from previous buybacks—as partial payment for 2025 directors’ fees. The transfer was valued at S$957,157.70, leaving treasury shares at 215.33 million, down from 215.65 million before the move, the filing noted.

This isn’t a capital raise or a new market buy. Yet, the disclosure comes as the stock hovers near its 12-month high, maintaining a link between directors’ pay and the share price.

One filing this week highlighted strength in the group’s Malaysia retail platform. CapitaLand Investment revealed that its subsidiary, the manager of CapitaLand Malaysia Trust, posted a 20.1% jump in fourth-quarter distributable income, the cash available for payouts.

CapitaLand Ascott Trust, managed by subsidiaries of CapitaLand Investment, reported an 11% jump in income available for distribution, hitting S$256.7 million for the year ending Dec. 31, 2025. The full-year distribution per stapled security came in at 6.10 Singapore cents. “CLAS continued to deliver stable distributions despite ongoing macroeconomic uncertainties,” said Lui Chong Chee, chairman of the trust’s managers, in the release. SGX Links

On Thursday, SGX released a notice detailing end-2025 valuations for CapitaLand Ascott Trust’s real estate, referencing reports from Colliers, CBRE, and JLL. The valuations stood at roughly S$4.40 billion, S$2.13 billion, and S$1.33 billion, respectively—key numbers supporting net asset value estimates.

The immediate issue is if those trends will boost fee income at the parent company. Equally crucial is whether management signals plans for more asset recycling or new fund launches in 2026. Singapore’s results season has heightened scrutiny on capital returns and balance-sheet discipline.

The downside remains clear: rising global yields or a cooling transaction market could weigh on property values and deal-related fees. If capital recycling slows, performance fees and investor sentiment might quickly take a hit.

CapitaLand Investment plans to unveil its unaudited full-year 2025 results ahead of the market open on Feb. 11, per an SGX notice — marking the next key event for the stock.

Stock Market Today

  • ServiceNow Stock Falls 3.39% Amid Mixed Tech Sector Signals
    June 9, 2026, 10:44 AM EDT. ServiceNow Inc (NOW) opened down 3.39% on June 9, weighed by company-specific factors despite broader tech sector rebounds. The stock declined following its April earnings report, which showed 22% subscription revenue growth and raised guidance but highlighted acquisition costs from Armis that may reduce 2026 margins. Analyst views remain mixed: while many maintain a Buy rating with upside potential, concerns over AI disruption and software spending softness persist. Technical indicators provide a neutral to mixed outlook, with MACD signaling buy but RSI and Williams %R suggesting caution. Broader macroeconomic factors, including strong U.S. jobs data pushing interest rate hike expectations, also pressure tech growth stocks like ServiceNow. The Nasdaq showed selective tech recovery amid recent volatility.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Accenture stock slides 3% as new share award pool wins approval — what investors watch next
Previous Story

Accenture stock slides 3% as new share award pool wins approval — what investors watch next

GSK share price dips in London as Exdensur rollout and Feb 4 results loom
Next Story

GSK share price dips in London as Exdensur rollout and Feb 4 results loom

Go toTop